Axa’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,789
| Closed | -$763K | – | 70 |
|
|
2026
Q1 | $763K | Buy |
+5,789
| New | +$768K | 0.3% | 49 |
|
|
2025
Q3 | – | Sell |
-341,734
| Closed | -$43M | – | 698 |
|
|
2025
Q2 | $43M | Buy |
341,734
+8,035
| +2% | +$921K | 0.12% | 154 |
|
|
2025
Q1 | $36.9M | Buy |
333,699
+35,995
| +12% | +$4.56M | 0.12% | 175 |
|
|
2024
Q4 | $40.6M | Buy |
297,704
+28,532
| +11% | +$3.53M | 0.12% | 162 |
|
|
2024
Q3 | $31M | Sell |
269,172
-14,850
| -5% | -$2.04M | 0.09% | 211 |
|
|
2024
Q2 | $39.1M | Buy |
284,022
+40,333
| +17% | +$5.53M | 0.12% | 173 |
|
|
2024
Q1 | $33.6M | Buy |
243,689
+127,478
| +110% | +$17.4M | 0.1% | 202 |
|
|
2023
Q4 | $15.3M | Sell |
116,211
-2,718
| -2% | -$313K | 0.05% | 319 |
|
|
2023
Q3 | $13.4M | Buy |
118,929
+31,664
| +36% | +$3.33M | 0.05% | 337 |
|
|
2023
Q2 | $8.23M | Buy |
87,265
+35,604
| +69% | +$3.48M | 0.03% | 450 |
|
|
2023
Q1 | $5.23M | Sell |
51,661
-19,158
| -27% | -$1.99M | 0.02% | 556 |
|
|
2022
Q4 | $8.46M | Sell |
70,819
-20,504
| -22% | -$2.4M | 0.03% | 471 |
|
|
2022
Q3 | $9.7M | Sell |
91,323
-16,947
| -16% | -$1.72M | 0.04% | 436 |
|
|
2022
Q2 | $10.6M | Buy |
108,270
+49,602
| +85% | +$4.58M | 0.04% | 425 |
|
|
2022
Q1 | $5.5M | Buy |
+58,668
| New | +$4.97M | 0.02% | 619 |
|
|
2021
Q4 | – | Sell |
-6,200
| Closed | -$595K | – | 1246 |
|
|
2021
Q3 | $595K | Hold |
6,200
| – | – | ﹤0.01% | 1041 |
|
|
2021
Q2 | $603K | Buy |
6,200
+4,125
| +199% | +$395K | ﹤0.01% | 1069 |
|
|
2021
Q1 | $202K | Sell |
2,075
-13,766
| -87% | -$1.44M | ﹤0.01% | 1177 |
|
|
2020
Q4 | $1.52M | Sell |
15,841
-54,215
| -77% | -$5.24M | ﹤0.01% | 907 |
|
|
2020
Q3 | $6.74M | Sell |
70,056
-20,255
| -22% | -$2.34M | 0.02% | 553 |
|
|
2020
Q2 | $11M | Buy |
90,311
+10,111
| +13% | +$1.12M | 0.04% | 404 |
|
|
2020
Q1 | $6.94M | Buy |
80,200
+6,108
| +8% | +$598K | 0.03% | 444 |
|
|
2019
Q4 | $7.96M | Buy |
+74,092
| New | +$7.76M | 0.03% | 502 |
|
|
2018
Q4 | – | Sell |
-68,822
| Closed | -$8.46M | – | 1349 |
|
|
2018
Q3 | $8.46M | Sell |
68,822
-14,730
| -18% | -$1.67M | 0.03% | 521 |
|
|
2018
Q2 | $8.21M | Buy |
83,552
+1,063
| +1% | +$95.2K | 0.03% | 513 |
|
|
2018
Q1 | $6.84M | Sell |
82,489
-65,221
| -44% | -$5.51M | 0.03% | 559 |
|
|
2017
Q4 | $11.5M | Sell |
147,710
-148
| -0.1% | -$10.1K | 0.05% | 424 |
|
|
2017
Q3 | $9.06M | Buy |
147,858
+56,972
| +63% | +$3.01M | 0.04% | 466 |
|
|
2017
Q2 | $4.18M | Sell |
90,886
-3,452
| -4% | -$167K | 0.02% | 648 |
|
|
2017
Q1 | $4.08M | Buy |
+94,338
| New | +$4.04M | 0.02% | 635 |
|
|
2015
Q3 | – | Sell |
-289,707
| Closed | -$13.8M | – | 1487 |
|
|
2015
Q2 | $13.8M | Hold |
289,707
| – | – | 0.06% | 330 |
|
|
2015
Q1 | $11.5M | Sell |
289,707
-52,446
| -15% | -$1.88M | 0.05% | 371 |
|
|
2014
Q4 | $7.64M | Sell |
342,153
-17,682
| -5% | -$335K | 0.03% | 456 |
|
|
2014
Q3 | $5.64M | Sell |
359,835
-2,310
| -0.6% | -$34.5K | 0.02% | 505 |
|
|
2014
Q2 | $5.37M | Buy |
362,145
+54,677
| +18% | +$772K | 0.02% | 523 |
|
|
2014
Q1 | $4.95M | Sell |
307,468
-31,813
| -9% | -$544K | 0.02% | 524 |
|
|
2013
Q4 | $3.17M | Buy |
339,281
+57,058
| +20% | +$557K | 0.01% | 655 |
|
|
2013
Q3 | $3.19M | Buy |
282,223
+257,227
| +1,029% | +$3.54M | 0.02% | 636 |
|
|
2013
Q2 | $334K | Buy |
+24,996
| New | +$307K | ﹤0.01% | 1037 |
|
Other funds holding NBIX
Axa's NBIX Position: Q2 2026 in Review
Axa sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 5,789 shares — an estimated $763K sold.
Axa first reported a position in NBIX in Q2 2013 and held it in 39 quarters. The position peaked at $43M in Q2 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Axa reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
- Axa sold 5,789 Neurocrine Biosciences shares in Q2 2026, an estimated $763K.
- Axa first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 39 quarters.
- Axa's Neurocrine Biosciences position peaked at $43M in Q2 2025.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Axa's 13F filing for Q2 2026, filed 14 Aug 2026.